Bio-Thera Solutions has started dosing patients in a Phase I clinical trial of BAT4306F to treat relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.
The Chinese company will evaluate the safety and tolerability of BAT4306F as a single agent as part of the multicentre, open-label, dose-escalation trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial is expected to enrol patients with relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.
Key objectives of the trial comprise identifying maximum tolerated dose, dose-limiting toxicity, pharmacokinetics and recommended doses for subsequent Phase II clinical studies.
Bio-Thera Solutions CEO Shengfeng Li said: “Initiating our Phase I clinical trial for BAT4306F represents a major milestone for Bio-Thera Solutions as BAT4306F is our first clinical candidate developed for the treatment of hematologic malignancies.
“While the BAT4306F development plan will be initially focused on CD20-positive B-cell non-Hodgkin’s lymphoma, we believe BAT4306F also has great potential as a treatment for other hematologic malignancies.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBAT4306F is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced CD20 monoclonal antibody. It has shown improved potential in preclinical studies.
The drug is also a naturally occurring receptor found to be overexpressed in various types of hematologic malignancies.
The solution is currently under development for use as a single agent and in combination with other agents for multiple hematologic malignancies including relapsed / refractory CD20-positive B-cell non-Hodgkin’s lymphoma.
